FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382699041> ?p ?o ?g. }

• W4382699041 endingPage "219" @default.
• W4382699041 startingPage "211" @default.
• W4382699041 abstract "BackgroundFluvoxamine (FVX) is an antidepressant proposed to its immunomodulatory effects in preventing deterioration in mild and moderate COVID-19.MethodsAn open-label, 1:1 randomized controlled trial was assigned either combination therapy 50 mg twice daily of FVX for 10 days and favipiravir (FPV) or FPV alone to assess the efficacy in preventing disease progression in mild to moderate COVID-19 on the fifth day.Results134 mild COVID-19 patients received FPV and 132 received FVX/FPV, 31 moderate COVID-19 patients received FPV/Dexamethasone (FPV/Dex), and 30 received FVX/FPV/Dexamethasone (FVX/FPV/Dex). The intention-to-treat (ITT) analysis showed no difference of no clinical deterioration on the fifth day in both mild COVID-19 (100% in FPV vs. 97% in FVX/FPV) and moderate COVID-19 (83.9% in FPV/Dex vs. 86.7% in FVX/FPV/Dex). However, there was a low rate of oxygen supplemental, hospitalization, or intensive care in both groups and zero death in all groups. No significant difference in oxygen supplemental, hospitalization, radiological, virological, or biochemical outcomes, and the immunomodulatory effect was observed between the group.ConclusionThe combined fluvoxamine treatment did not add benefit in preventing deterioration in mild-to-moderate COVID-19 patients without the immunomodulatory effect observed, although it demonstrated low hospitalization rates, oxygen supplemental, intensive care needed, and zero mortality.Trial RegistrationThai clinical trials registry (TCTR) no. 20210615002" @default.
• W4382699041 created "2023-07-01" @default.
• W4382699041 creator A5043632377 @default.
• W4382699041 creator A5049829812 @default.
• W4382699041 creator A5055463938 @default.
• W4382699041 creator A5060370694 @default.
• W4382699041 creator A5062685530 @default.
• W4382699041 creator A5078106985 @default.
• W4382699041 creator A5092368184 @default.
• W4382699041 creator A5092368185 @default.
• W4382699041 creator A5092368186 @default.
• W4382699041 date "2023-09-01" @default.
• W4382699041 modified "2023-10-18" @default.
• W4382699041 title "Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)" @default.
• W4382699041 cites W2137760779 @default.
• W4382699041 cites W2739679816 @default.
• W4382699041 cites W2942615395 @default.
• W4382699041 cites W3012721715 @default.
• W4382699041 cites W3015016176 @default.
• W4382699041 cites W3048223030 @default.
• W4382699041 cites W3088599398 @default.
• W4382699041 cites W3102920585 @default.
• W4382699041 cites W3128592226 @default.
• W4382699041 cites W3152668228 @default.
• W4382699041 cites W3165737823 @default.
• W4382699041 cites W3208556307 @default.
• W4382699041 cites W3211452561 @default.
• W4382699041 cites W3217322372 @default.
• W4382699041 cites W3217600890 @default.
• W4382699041 cites W3217735618 @default.
• W4382699041 cites W4200051875 @default.
• W4382699041 cites W4206009788 @default.
• W4382699041 cites W4221091296 @default.
• W4382699041 cites W4223573555 @default.
• W4382699041 cites W4224029848 @default.
• W4382699041 cites W4226236384 @default.
• W4382699041 cites W4292148078 @default.
• W4382699041 cites W4311752762 @default.
• W4382699041 cites W4366140579 @default.
• W4382699041 doi "https://doi.org/10.1016/j.ijid.2023.06.018" @default.
• W4382699041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37393041" @default.
• W4382699041 hasPublicationYear "2023" @default.
• W4382699041 type Work @default.
• W4382699041 citedByCount "1" @default.
• W4382699041 crossrefType "journal-article" @default.
• W4382699041 hasAuthorship W4382699041A5043632377 @default.
• W4382699041 hasAuthorship W4382699041A5049829812 @default.
• W4382699041 hasAuthorship W4382699041A5055463938 @default.
• W4382699041 hasAuthorship W4382699041A5060370694 @default.
• W4382699041 hasAuthorship W4382699041A5062685530 @default.
• W4382699041 hasAuthorship W4382699041A5078106985 @default.
• W4382699041 hasAuthorship W4382699041A5092368184 @default.
• W4382699041 hasAuthorship W4382699041A5092368185 @default.
• W4382699041 hasAuthorship W4382699041A5092368186 @default.
• W4382699041 hasBestOaLocation W43826990411 @default.
• W4382699041 hasConcept C126322002 @default.
• W4382699041 hasConcept C168563851 @default.
• W4382699041 hasConcept C170493617 @default.
• W4382699041 hasConcept C2775864247 @default.
• W4382699041 hasConcept C2776134451 @default.
• W4382699041 hasConcept C2779134260 @default.
• W4382699041 hasConcept C2779772310 @default.
• W4382699041 hasConcept C2779910183 @default.
• W4382699041 hasConcept C2780401358 @default.
• W4382699041 hasConcept C3008058167 @default.
• W4382699041 hasConcept C42219234 @default.
• W4382699041 hasConcept C524204448 @default.
• W4382699041 hasConcept C535046627 @default.
• W4382699041 hasConcept C71924100 @default.
• W4382699041 hasConceptScore W4382699041C126322002 @default.
• W4382699041 hasConceptScore W4382699041C168563851 @default.
• W4382699041 hasConceptScore W4382699041C170493617 @default.
• W4382699041 hasConceptScore W4382699041C2775864247 @default.
• W4382699041 hasConceptScore W4382699041C2776134451 @default.
• W4382699041 hasConceptScore W4382699041C2779134260 @default.
• W4382699041 hasConceptScore W4382699041C2779772310 @default.
• W4382699041 hasConceptScore W4382699041C2779910183 @default.
• W4382699041 hasConceptScore W4382699041C2780401358 @default.
• W4382699041 hasConceptScore W4382699041C3008058167 @default.
• W4382699041 hasConceptScore W4382699041C42219234 @default.
• W4382699041 hasConceptScore W4382699041C524204448 @default.
• W4382699041 hasConceptScore W4382699041C535046627 @default.
• W4382699041 hasConceptScore W4382699041C71924100 @default.
• W4382699041 hasFunder F4320316404 @default.
• W4382699041 hasLocation W43826990411 @default.
• W4382699041 hasLocation W43826990412 @default.
• W4382699041 hasOpenAccess W4382699041 @default.
• W4382699041 hasPrimaryLocation W43826990411 @default.
• W4382699041 hasRelatedWork W1511775759 @default.
• W4382699041 hasRelatedWork W1990941510 @default.
• W4382699041 hasRelatedWork W2011717172 @default.
• W4382699041 hasRelatedWork W2067693794 @default.
• W4382699041 hasRelatedWork W2153052119 @default.
• W4382699041 hasRelatedWork W261798218 @default.
• W4382699041 hasRelatedWork W3092613758 @default.
• W4382699041 hasRelatedWork W3185137146 @default.
• W4382699041 hasRelatedWork W4245460973 @default.
• W4382699041 hasRelatedWork W4256514411 @default.

• next